U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H28N2O4
Molecular Weight 348.4373
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROXATIDINE ACETATE

SMILES

CC(=O)OCC(=NCCCOc1cccc(c1)CN2CCCCC2)O

InChI

InChIKey=SMTZFNFIKUPEJC-UHFFFAOYSA-N
InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.drugsupdate.com/generic/view/456/Roxatidine | https://www.ncbi.nlm.nih.gov/pubmed/1717223 | https://www.ncbi.nlm.nih.gov/pubmed/20718616

Roxatidine is an histamine H2-receptor antagonist. Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action. Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome also it can be used as a premedication before anaesthesia. Roxatidine possessed a robust estrogenic activity.

CNS Activity

Curator's Comment:: Small amounts of roxatidine were detectable in the CSF, the CSF to plasma ratio ranging from 0 to 0.89.

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
PubMed

PubMed

TitleDatePubMed
Histamine H2-receptor antagonistic action of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)acetoxyacetamide hydrochloride (TZU-0460).
1985
Penetration of roxatidine into the cerebrospinal fluid.
1988
Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
1991 Aug
Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation.
2017 Jan 31
Patents

Sample Use Guides

Peptic ulcer: 150 mg at bedtime or 75 mg bid daily for 4-6 weeks. Maintenance: 75 mg at bedtime.
Route of Administration: Other
6.25-25 uM Roxatidine suppressed the PMACI-induced production of pro-inflammatory cytokines in HMC-1
Name Type Language
ROXATIDINE ACETATE
MI   VANDF   WHO-DD  
Common Name English
ACETAMIDE, 2-(ACETYLOXY)-N-(3-(3-(1-PIPERIDINYLMETHYL)PHENOXY)PROPYL-
Common Name English
ROXATIDINE ACETATE [VANDF]
Common Name English
PIFATIDINE
Common Name English
ROXATIDINE ACETATE [MI]
Common Name English
ROXATIDINE ACETATE [WHO-DD]
Common Name English
Code System Code Type Description
RXCUI
35803
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY RxNorm
EVMPD
SUB04277MIG
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY
EPA CompTox
78628-28-1
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY
CAS
78628-28-1
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY
MERCK INDEX
M9677
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY Merck Index
PUBCHEM
5105
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY
DRUG CENTRAL
2408
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY
FDA UNII
ZUP3LSD0DO
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY
ChEMBL
CHEMBL46102
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY
MESH
C053742
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY
DRUG BANK
DB08806
Created by admin on Sat Jun 26 03:17:02 UTC 2021 , Edited by admin on Sat Jun 26 03:17:02 UTC 2021
PRIMARY